Focused Issue Dedicated to the Congress on Clinical Controversies in Lung Cancer (CCLC 2018)

Posted On 2019-06-25 11:06:05


This focused issue dedicated to the Dedicated to the Congress on Clinical Controversies in Lung Cancer (CCLC 2018) is edited by Prof. Nir Peled, Oncology Division, the Legacy Heritage Oncology Center & Larry Norton Institute, Soroka Medical Center, Ben-Gurion University, Beer-Sheva, Israel.

Prof. Peled is the head of the Oncology Division at the Legacy Heritage Oncology Center & Larry Norton Institute at Soroka Medical Center, Ben-Gurion University, Beer-Sheva, Israel. He practices mainly in the field of thoracic oncology and is one of the key opinion leaders in that field. He is the chair of the thoracic cancer Assembly of the European Thoracic Society and a co-chair of the screening committee of the IASLC. Prof. Peled’ research focuses on the wide translational and clinical perspectives of lung cancer, including personalized targeted therapy in lung cancer, biomarkers development and early detection of this disease.

Focused issue outline:
  1. Preface to This Focused Issue
    Nir Peled, Oncology Division, the Legacy Heritage Oncology Center & Larry Norton Institute, Soroka Medical Center, Ben-Gurion University, Beer-Sheva, Israel
  2. SBRT for Early Disease
    Aaron Allen, Department of Radiation Oncology, Davidoff Center, Rabin Medical Center, Petah Tikva, Israel
  3. Do we have a Maximum Lesions for Brain SRS?
    Deborah Blumenthal, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
  4. Challenges in the Pathology Lab
    Phillipe Taniere, Department of Cellular Pathology, Queen Elizabeth Hospital, Queen Elizabeth Medical Centre, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
  5. ALK disease: best first or later, and do we care about variants?
    Petros Christopoulos, Department of Thoracic Oncology, Thoraxklinik and National Center for Tumor Diseases (NCT) at Heidelberg University Hospital, Heidelberg, Germany
  6. Disease progression in non-small cell lung cancer on immune-checkpoint inhibition, what are the options?
    Rudolf M. Huber, Division of Respiratory Medicine and Thoracic Oncology, Department of Medicine, University of Munich – Campus Innenstadt, Ziemssenstraße 1, Munich, Germany
  7. Annotating the NGS Report - Who's responsibility?
    Miguel Angel Molina , Pangaea Oncology, Laboratory of Molecular Biology, Quirón-Dexeus University Institute, Barcelona, Spain
  8. What are the Best Biomarkers for IO in Lung Cancer?
    Miguel Angel Molina , Pangaea Oncology, Laboratory of Molecular Biology, Quirón-Dexeus University Institute, Barcelona, Spain
  9. Is There a Recommend Methodology in Screening Programs?
    Matthijs Oudkerk & Joan Walter, University of Groningen, University Medical Center Groningen, Center for Medical Imaging - North East Netherlands, Groningen, The Netherlands
  10. Are we Facing a Revolution in Screening for Lung Cancer in Europe Now?
    Robert Pirker, Department of Medicine I, Medical University of Vienna, Vienna, Austria
  11. Recent Updates in Immunotherapy in Lung Cancer (NSCLC & SCLC)
    Nir Peled, Oncology Division, the Legacy Heritage Oncology Center & Larry Norton Institute, Soroka Medical Center, Ben-Gurion University, Beer-Sheva, Israel
  12. Bio-Informatics - Outsource or in-house Analysis?
    Laila C. Roisman, Institute of Oncology, Davidoff Cancer Center, Rabin Medical Center, Petach Tikva, Israel
  13. PCI or MRI Monitoring in Limited SCLC: is it a question?
    Paul Van Houtte , Department of Radiation Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium